SAN DIEGO and GOTHENBURG, May 1, 2017 – ProSciento, a full scope clinical R&D services provider focused on diabetes, NASH and obesity, and Antaros Medical, an advanced clinical imaging research and methodology company, will present scientific data at the 2nd International NASH Biomarkers Workshop in Washington, DC, May 5-6, 2017.
The poster presentation titled ‘On the Importance of Assessing the Entire Liver in MRI-PDFF Studies of Liver Fat’ summarizes data from a clinical study conducted at Uppsala University to assess changes in liver fat and liver volume following caloric restriction in subjects with morbid obesity. Analysis of fat fraction (%) using a single or multiple region of interest (ROI) approach was compared to analysis across the entire liver using a semi-automated approach developed by Antaros. Results point to several advantages of the later, including improved precision and simultaneous assessment of liver volume, as a means to control for confounders such as liver glycogen and water content. These findings have potential implications for the assessment of liver fat in pharmaceutical intervention studies, including sample size requirements.
About the 2nd International NASH Biomarkers Workshop
The NASH Biomarkers Workshop is an international cross-disciplinary forum that brings together clinical and translational research experts for in-depth discussions of the latest advances in the development of biomarkers for NASH. The NASH Biomarkers Workshop is co-organized by the Liver Forum and Expert Medical Events. For more information, visit http://expertmedicalevents.com/event/upcoming/nash-biomarkers-2017/.
About Antaros Medical
Antaros Medical is a drug development technology innovator based in the BioventureHub at AstraZeneca Gothenburg and in Uppsala, Sweden. Antaros Medical is pioneering new frontiers in innovative imaging methodologies to design and deliver clinical studies for improved, evidence-based decision making in clinical drug development. The company is specialized in cardio-metabolic diseases and oncology. Antaros Medical’s clients are spread across the globe. For more information, visit www.antarosmedical.com.
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.nashpass.wpengine.com.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
For business development inquires:
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427